PLos One:组织学亚型与肺癌中的肌肉减少症无关

2018-03-29 xiangting MedSci原创

这项研究发现肌肉减少症与LCA中的老年、男性、晚期、合并症和低BMI显著相关。然而,组织学亚型并不是肌肉减少症存在的独立因素。

肌肉减少症很常见,并且是已知的肺癌(LCA)不良预后效应物。然而,LCA中肌肉减少症与组织学之间的关系仍不明确。

研究人员回顾性分析了2012年6月至2015年2月新诊断的LCA患者(n = 778),以确定与肌肉减少症相关的因素。肌肉减少症定义为CT确定的L3肌指数(L3的肌肉面积/身高2):男性<55cm 2/m2,女性<39cm2/m2。

患者平均年龄为67.7±10.8岁,大部分(73.1%)为男性。最常见的组织学类型是腺癌(44.0%),71.6%患者为III期或IV期。肌肉减少症的总患病率为48.2%(男性为60.3%,女性为15.3%)。单变量分析显示,肌肉减少症与男性,年龄(≥65岁),吸烟状况,较低的BMI(<23kg/m2),晚期(III和IV期)和高合并症评分(Charlson指数≥3)显著相关。此外,鳞状细胞癌(54.9%)和小细胞LCA(56.4%)的肌肉减少症的患病率高于腺癌(39.8%)。多变量分析显示,肌肉减少症与男性(OR,11.13),老年人(OR,2.02)和低BMI(OR,6.28),IV期(OR,1.98)和高合并症(OR, 1.93)独立相关。然而,没有发现组织学亚型和肌肉减少症之间存在显著关联。

这项研究发现肌肉减少症与LCA中的老年、男性、晚期、合并症和低BMI显著相关。然而,组织学亚型并不是肌肉减少症存在的独立因素。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647087, encodeId=9258164e08753, content=<a href='/topic/show?id=fd6d809e535' target=_blank style='color:#2F92EE;'>#肌肉减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80975, encryptionId=fd6d809e535, topicName=肌肉减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18723374958, createdName=shizhenshan, createdTime=Fri Feb 01 15:23:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926232, encodeId=db421926232a9, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Apr 21 16:23:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790131, encodeId=8f1a1e9013136, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Oct 04 23:23:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393383, encodeId=3660139338362, content=<a href='/topic/show?id=e2f4809e7e9' target=_blank style='color:#2F92EE;'>#肌肉减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80977, encryptionId=e2f4809e7e9, topicName=肌肉减少症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Mar 31 00:23:00 CST 2018, time=2018-03-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647087, encodeId=9258164e08753, content=<a href='/topic/show?id=fd6d809e535' target=_blank style='color:#2F92EE;'>#肌肉减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80975, encryptionId=fd6d809e535, topicName=肌肉减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18723374958, createdName=shizhenshan, createdTime=Fri Feb 01 15:23:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926232, encodeId=db421926232a9, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Apr 21 16:23:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790131, encodeId=8f1a1e9013136, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Oct 04 23:23:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393383, encodeId=3660139338362, content=<a href='/topic/show?id=e2f4809e7e9' target=_blank style='color:#2F92EE;'>#肌肉减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80977, encryptionId=e2f4809e7e9, topicName=肌肉减少症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Mar 31 00:23:00 CST 2018, time=2018-03-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647087, encodeId=9258164e08753, content=<a href='/topic/show?id=fd6d809e535' target=_blank style='color:#2F92EE;'>#肌肉减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80975, encryptionId=fd6d809e535, topicName=肌肉减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18723374958, createdName=shizhenshan, createdTime=Fri Feb 01 15:23:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926232, encodeId=db421926232a9, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Apr 21 16:23:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790131, encodeId=8f1a1e9013136, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Oct 04 23:23:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393383, encodeId=3660139338362, content=<a href='/topic/show?id=e2f4809e7e9' target=_blank style='color:#2F92EE;'>#肌肉减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80977, encryptionId=e2f4809e7e9, topicName=肌肉减少症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Mar 31 00:23:00 CST 2018, time=2018-03-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647087, encodeId=9258164e08753, content=<a href='/topic/show?id=fd6d809e535' target=_blank style='color:#2F92EE;'>#肌肉减少#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80975, encryptionId=fd6d809e535, topicName=肌肉减少)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d18723374958, createdName=shizhenshan, createdTime=Fri Feb 01 15:23:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926232, encodeId=db421926232a9, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sat Apr 21 16:23:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790131, encodeId=8f1a1e9013136, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Oct 04 23:23:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1393383, encodeId=3660139338362, content=<a href='/topic/show?id=e2f4809e7e9' target=_blank style='color:#2F92EE;'>#肌肉减少症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80977, encryptionId=e2f4809e7e9, topicName=肌肉减少症)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Mar 31 00:23:00 CST 2018, time=2018-03-31, status=1, ipAttribution=)]

相关资讯

马大爷的糟心事:他的肺究竟怎么了?

根据上图,于左肺上叶近主动脉弓旁见一软组织样密度影,与主动脉弓分界不清,周边似见分叶征象,怀疑肺癌可能。

Drug Safety:钙通道阻滞剂或增加肺癌风险

发表在《Drug Saf》的一项由以色列和加拿大科学家进行的观察性研究的系统评价和Meta分析,考察了钙通道阻滞剂(CCB)与肺癌风险之间的相关性。

Thorax:癌症治疗的地理差异与肺癌患者的生存率相关

不同治疗方式的使用程度在英国各地区之间有所不同。这些差异并不能归因于接受检查的患者和肿瘤特征,而是更多的反映了当地多学科团队在临床治疗方面的差异。

Lancet Oncol:EGFR/ALK阳性的NSCLC多线靶向治疗后仍可用免疫治疗?

抗PD-L1单抗durvalumab目前已经获批用于接受了同步放化疗后未进展的局部晚期NSCLC的维持治疗。近日,durvalumab用于晚期NSCLC三线或以上治疗的II期临床试验ATLANTIC研究结果在《Lancet Oncology》杂志发表。

病例分享:MRI引导下肺肿瘤热消融治疗是中晚期肺癌患者的有效治疗选择

MRI引导下肺肿瘤热消融治疗是安全、有效的,消融后疗效评价优于CT,对于早期肺癌具有根治效果,是中晚期肺癌及肺转移癌综合治疗中的有效手段。由于CT对肺部肿瘤良好显示能力及普及率高,以及MRI设备及MRI兼容性器械的特殊性,目前国内外开展MRI引导下肺肿瘤热消融治疗较少,仍处于探索、起步阶段。

Ann Oncol:依诺肝素联合标准疗法能否改善小细胞肺癌患者的总生存率?

2018年2月,发表在《Ann Oncol》上的一项研究,对低分子量肝素(LMWH)依诺肝素联合标准疗法治疗小细胞肺癌(SCLC)患者的生存情况进行了考察。